Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Biol Chem ; 403(8-9): 869-890, 2022 07 26.
Article in English | MEDLINE | ID: mdl-34450690

ABSTRACT

To improve management of head and neck squamous cell carcinoma patients, we need to increase our understanding of carcinogenesis, to identify biomarkers, and drug targets. This study aimed to identify novel biomarkers by providing transcriptomics profiles of matched primary tumors, lymph node metastasis, and non-malignant tissue of 20 HNSCC patients as well as by bioinformatic analyses of a TCGA HNSCC cohort, comprising 554 patients. We provide cancer cell signaling networks differentially expressed in tumors versus metastases, such as mesenchymal-epithelial transition, and structural integrity networks. As a proof of principle study, we exploited the data sets and performed functional analyses of a novel cytokeratin, cytokeratin24 (cKRT24), which had not been described as biomarker for tumors before. Survival analysis revealed that low cKRT24 expression correlated with poor overall survival in HNSCC. Experimentally, downregulation of cKRT24 in primary tumors, metastases, and HNSCC cell lines was verified on mRNA and protein level. Cloning and ectopic overexpression of cKRT24 not only affected viability and growth of HNSSC cell lines, but also inhibited tumor growth in murine xenograft studies. We conclude that cKRT24 functions as a tumor suppressor in HNSCC, and may serve as an additional prognostic biomarker and novel target to support current HNSCC treatments.


Subject(s)
Genes, Tumor Suppressor , Head and Neck Neoplasms , Keratins, Type I , Squamous Cell Carcinoma of Head and Neck , Animals , Biomarkers, Tumor/genetics , Carcinogenesis/genetics , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Head and Neck Neoplasms/genetics , Humans , Keratins, Type I/genetics , Mice , Squamous Cell Carcinoma of Head and Neck/genetics
2.
Cancers (Basel) ; 12(11)2020 Nov 13.
Article in English | MEDLINE | ID: mdl-33202816

ABSTRACT

This study aimed to assess the distribution of growth factor receptors in oropharyngeal squamous cell cancer (OPSCC) and evaluate their role in the context of human papillomavirus (HPV) status, prognosis and potential relevance for targeted therapy. The protein expression of human epidermal growth factor receptor (Her)1-4 and c-Met were retrospectively assessed using semiquantitative immunohistochemistry on tissue microarrays and analyzed for correlations as well as differences in the clinicopathological criteria. Her1-4 and c-met were overexpressed compared to normal mucosa in 46%, 4%, 17%, 27% and 23%, respectively. Interestingly, most receptors were coexpressed. Her1 and c-Met were inversely correlated with p16 (p = 0.04; p = 0.02). Her2 and c-Met were associated with high tobacco consumption (p = 0.016; p = 0.04). High EGFR, Her3, Her4 and c-Met expression were associated with worse overall and disease-free survival (p ≤ 0.05). Furthermore, EGFR and c-Met expression showed raised hazard ratios of 2.53 (p = 0.02; 95% CI 1.24-5.18) and 2.45 (p = 0.02; 95% CI 1.13-5.35), respectively. Her4 was expressed less in distant metastases than in corresponding primary tumors and was correlated to a higher T category. EGFR and c-Met are relevant negative prognostic factors in OPSCC, independent of known clinicopathological parameters. We suggest dual targeting of EGFR and c-Met as a promising strategy for OPSCC treatment.

3.
Eur J Surg Oncol ; 45(6): 1046-1053, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30857877

ABSTRACT

INTRODUCTION: Recognizing the prognostic power differentiating HPV-associated oropharyngeal squamous cell cancer (OPSCC) from OPSCC with other causes, the UICC Cancer Staging Manual 8th edition realizes significant changes from the 7th edition. Purpose of this study was to evaluate the differences of prognostic impact between the 7th and the latest edition of TNM Classification as well as to examine risk factors like extranodal extension (ENE) and lymph node ratio (LNR) for HPV-mediated OPSCC. MATERIAL AND METHODS: The study includes 255 patients with OPSCC and initial diagnosis between 2008 and 2015. HPV status was determined according to p16 immunohistochemistry (IHC) and all patients were classified as defined by 7th and 8th edition of UICC. Prognostic influence of ENE and LNR was analyzed for patients with HPV-mediated OPSCC. RESULTS: 41.2% of the OPSCC were p16-positive. Implementation of the 8th edition of the UICC lead to a better differentiation between the respective stages. Regarding HPV-positive OPSCC, Kaplan-Meier survival curves showed a significantly better overall survival (OS) for patients with a LNR ≤10% as well as for patients with negative ENE status (p = 0.004, p = 0.008). CONCLUSION: 8th edition of UICC achieves to differentiate properly between the UICC stages. However, the staging rule of ignoring ENE in HPV-mediated OPSCC should be further analyzed. Moreover LNR might be a possible additional prognostic factor - especially regarding HPV-positive tumors.


Subject(s)
Head and Neck Neoplasms/diagnosis , Neoplasm Staging/methods , Oropharyngeal Neoplasms/diagnosis , Squamous Cell Carcinoma of Head and Neck/diagnosis , Female , Follow-Up Studies , Germany/epidemiology , Head and Neck Neoplasms/mortality , Humans , Immunohistochemistry , Male , Middle Aged , Oropharyngeal Neoplasms/mortality , Prognosis , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck/mortality , Survival Rate/trends
4.
Methods Mol Biol ; 1574: 227-241, 2017.
Article in English | MEDLINE | ID: mdl-28315255

ABSTRACT

In this chapter, you will learn how to use translocation biosensors to investigate protease functions in living cells. We here present modular protein translocation biosensors tailored to investigate protease activity and protein-protein interactions. Besides the mapping of protease function, the biosensors are also applicable to identify chemicals and/or (nano)materials modulating the respective protein activities and can also be exploited for RNAi-mediated genetic screens.


Subject(s)
Biological Assay/methods , Drug Discovery/methods , Endopeptidases/metabolism , Protease Inhibitors/pharmacology , Protein Transport , Biosensing Techniques/methods , Gene Expression , Genes, Reporter , Genetic Vectors/genetics , High-Throughput Screening Assays , Microscopy, Fluorescence , Protein Binding , Proteolysis , Substrate Specificity
SELECTION OF CITATIONS
SEARCH DETAIL